Panel Discussion: Building a Unified Global Framework to Enable Scalable Phage Development, Investment Confidence & Market Access

  • Comparing evolving regulatory approaches across regions to identify opportunities for alignment that de-risk development for investors
  • Evaluating how harmonised guidance could accelerate approval timelines, reduce duplicated effort and strengthen the commercial case for phage therapies
  • Exploring how global partnerships, data-sharing initiatives and transparent evidence standards can unlock greater investment, set new regulatory precedents and enable scalable, sustainable phage innovation